A Phase II Study of the Effects of Herceptin in Patients With Locally Advanced HER-2/NEU Overexpressing Breast Cancer
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- The effects of Herceptin and its efficacy in women with HER-2 overexpressing advanced breast cancer
研究概览
简要总结
The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin, together with chemotherapy, is in treating advanced breast cancer.
详细描述
We want to determine the effects of Herceptin and to determine its efficacy in women with HER-2 overexpressing advanced breast cancer. The end-points will include the comparison of an array of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin.
The other aim of this study would be to determine clinical response to therapy with Herceptin and Taxotere.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •All patients must be female.
- •Informed consent must be signed.
- •Women with locally advanced breast cancers or primary breast cancers with concomitant gross metastatic disease are eligible. Locally advanced cancers must be of clinical and/or radiologic size > 4 cm, and/or are deemed surgically inoperable.
- •Her2/neu overexpressing tumors defined as HercepTest score of 3+, or >/= one-third of invasive tumor showing membranous staining, or fluorescence in situ hybridization (FISH) positive.
- •Negative serum pregnancy test (bHCG) within 7 days of starting study, if of child-bearing potential.
- •Kidney and liver function tests - all within 1.5 times of the institution's upper limit of normal.
- •Performance status (World Health Organization [WHO] scale) < 2 and life expectancy > 6 months.
- •No metastatic disease without concomitant primary breast cancer.
- •No previous or current malignancies at other sites within the last 5 years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin.
排除标准
- •Pregnancy or unwillingness to use a reliable contraceptive method in women of child-bearing potential.
- •Severe underlying chronic illness or disease.
- •Cardiomyopathy or baseline left ventricular ejection fraction (LVEF) < 50%.
- •Patients on other investigational drugs while on study.
- •Severe or uncontrolled hypertension defined as blood pressure (BP) > 180/100 on three separate occasions.
- •History of congestive heart failure.
- •History of coronary arterial disease.
研究组 & 干预措施
Heceptin
Herceptin administered to enrolled subjects
干预措施: Herceptin (Drug)
结局指标
主要结局
The effects of Herceptin and its efficacy in women with HER-2 overexpressing advanced breast cancer
时间窗: 1 year
A comparison of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin
次要结局
- To determine clinical response to therapy with Herceptin and Taxotere(one year)
研究者
Mothaffar Rimawi
Medical Director
Baylor Breast Care Center